Abstract The p21-activated kinase 4 (PAK4) is a key downstream effector of the Rho family
GTPases and is found to be overexpressed in pancreatic ductal adenocarcinoma (PDAC) …

In many types of cancers, pyruvate dehydrogenase kinase (PDK) is abnormally
overexpressed and has become a promising target for cancer therapy. However, few highly …

Abstract Pyruvate dehydrogenase kinase 3 (PDK3) is a multifunctional enzyme that plays a
central role in the cancer metabolic switch by blocking pyruvate catabolism in the TCA cycle …

The emergence of protein kinase D (PKD) as a potential therapeutic target for several
diseases including cancer has triggered the search for potent, selective, and cell-permeable …

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy and is highly
resistant to standard treatment regimens. Targeted therapies against KRAS, a mutation …

Cancer cells alter their metabolism to support the uninterrupted supply of biosynthetic
molecules required for continuous proliferation. Glucose metabolism is frequently …

Pyruvate dehydrogenase kinase PDK1 is a metabolic enzyme responsible for switching
glucose metabolism from mitochondrial oxidation to aerobic glycolysis in cancer cells, a …

Purpose: Improved therapeutic approaches are needed for the treatment of pancreatic
ductal adenocarcinoma (PDAC). As dual MEK and PI3K inhibition is presently being used in …

Simple Summary Small molecule inhibitors and targeted therapy are considered to have
significant potential for pancreatic ductal adenocarcinoma therapies. Preclinical studies of …

Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers with dismal
survival rates. Its intransigence to conventional therapy renders PDAC an aggressive …